Acura Pharmaceuticals (ACUR) says it's received notification from a generic sponsor of its filing of an Abbreviated New Drug Application for a generic version of Oxecta Tablets, saying it believes Acura's patents are invalid, unenforceable or not infringed. Pfizer (PFE) licenses Oxecta, but it's covered by U.S. patents issued to ACUR, who says it intends to take appropriate action to enforce its intellectual property.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs